Naloxone hydrochloride

LYONS, Colo., Jan. 28, 2026 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to prevent and reverse overdoses caused by highly potent, synthetic opioids especially when ingested orally, today announced that it has completed a $7.5 million SAFE round. Elysium intends to accelerate development of its SOOPR™ (Synthetic Opioid Overdose Protection and Reversal) technology designed specifically as a rescue treatment for overdoses brought on by synthetic opioids, including fentanyl and the emerging threat of more potent nitazenes. "With these funds in place, we have initiated work to progress our SOOPR technology through preclinical and clinical studies as we develop this important, life-saving technology to address the deadly overdose epidemic caused by illicit synthetic opioids," said Greg Sturmer, CEO of Elysium Therapeutics. "Our society continues to see far too many overdose fatalities, and we believe that our SOOPR technology has enormous potential to become the new standard for rescue and as a countermeasure as the illicit drug market evolves to progressively more dangerous opioids." SOOPR is a rapid-onset, long-acting rescue agent specifically designed to prevent and reverse overdoses from synthetic opioids, including oral fentanyl and nitazenes. SOOPR utilizes a proprietary naloxone prodrug formulation that offers more rapid onset and longer duration of action than current rescue agents (e.g., NARCAN, Kloxxado, Opvee). The technology is designed to rapidly restore respiration, reducing the risk of hypoxic brain injury and death, and provide 12 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization. Further, SOOPR delivers naloxone with a unique, infusion-like pharmacokinetic profile that is ideally suited to reduce the risk of severe withdrawal symptoms commonly associated with nalmefene and high-dose naloxone products. SOOPR is also intended to prevent same-day re-use of opioids and to offer an essential period for family members and healthcare professionals to assist the overdose patient in accessing medically-assisted therapy, which represents their best opportunity for long-term survival. Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus intranasal and intramuscular naloxone and a significantly longer duration of action. This profile is specifically designed to counteract oral fentanyl and nitazene overdoses associated with prolonged exposures that often outlast the short-acting profile of existing rescue agents. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl and nitazenes. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a fast-onset, long-acting opioid antagonist specifically designed to address oral synthetic opioid overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including NARCAN and Opvee. In addition, Elysium is also developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain, having achieved human proof-of-concept demonstrating a significant reduction in hydrocodone exposure in overdose scenarios versus generic hydrocodone. For more information, please visit . SOURCE Elysium Therapeutics 21% more press release views with Request a Demo

CMI deploys AI-powered digital intervention designed to increase consistent carriage of naloxone, a life-saving medication that reverses opioid overdoses. Naloxone saves lives only when it is carried and available. Our goal is to make consistent carriage the norm, not the exception.” — Steven Jenkins BOSTON, MA, UNITED STATES, January 21, 2026 / EINPresswire.com / -- Contingency Management Innovations (CMI) today announced a research collaboration with King’s College London (King’s) to develop and evaluate an AI-powered digital intervention designed to increase consistent carriage of naloxone , a proven, life-saving medication that reverses opioid overdoses. While naloxone distribution has expanded significantly in recent years, real-world impact is often limited by inconsistent carriage. Naloxone frequently is not present at the moment an overdose occurs—even among individuals most likely to witness one, including people who use opioids, peers, family members, and frontline staff. Closing this gap between access and availability represents one of the most immediate opportunities to reduce overdose mortality. The CMI–King’s initiative addresses this challenge by combining behavioral science, artificial intelligence, and evidence-based contingency management. The project will leverage CMI’s NIH-backed digital platform, enhanced with an AI-powered contextual agent that delivers personalized prompts, adaptive incentives, and real-time reinforcement to encourage routine naloxone carriage. The system dynamically adjusts engagement strategies based on behavioral patterns and contextual signals, promoting sustained behavior change while minimizing burden and stigma. “This collaboration brings together implementation-ready digital technology and world-class academic research to address a critical harm-reduction challenge,” said Steven Jenkins, CEO of Q2i, CMI’s parent company. “Naloxone saves lives only when it is carried and available. Our goal is to make consistent carriage the norm, not the exception.” Evaluation and implementation research will be led by investigators at King’s , drawing on the university’s internationally recognized expertise in addiction science, psychiatry, and public health. The study will examine feasibility, engagement, equity, and real-world effectiveness across diverse populations and settings, generating evidence to inform scale-up through health systems, community organizations, and public-sector programs. “Naloxone is one of the most effective tools we have to prevent overdose deaths, yet it too often isn’t present at the critical moment,” said Professor Sir John Strang, Professor of Addiction Psychiatry at King’s College London. “This collaboration applies rigorous behavioral science and advanced AI to a real-world harm-reduction challenge—supporting people to carry naloxone consistently and without stigma. Improving carriage rates has the potential to translate directly into lives saved, which is the ultimate measure of impact.” The initiative aligns with international and national public-health guidance. The World Health Organization has long endorsed community-based naloxone distribution and layperson overdose response as core harm-reduction strategies, while the Centers for Disease Control and Prevention and the U.S. Surgeon General explicitly recommend that individuals at risk of witnessing an overdose carry naloxone and be prepared to use it. By focusing on sustained carriage—rather than access alone—the CMI–King’s collaboration directly operationalizes these recommendations through scalable digital technology. Pending successful evaluation, the partners anticipate broader deployment across the U.K., U.S., and other jurisdictions seeking to strengthen overdose prevention efforts and reduce preventable loss of life. About Contingency Management Innovations (CMI) CMI develops AI-enabled digital contingency management platforms that improve engagement, adherence, and outcomes across substance-use and behavioral-health interventions. About King’s College London and the Institute of Psychiatry, Psychology & Neuroscience King’s College London is amongst the top 35 universities in the world and top 10 in Europe (THE World University Rankings 2023), and one of England’s oldest and most prestigious universities. Lawrence Klimczyk Contingency Managent Innovations Larry@contingency-management.com Visit us on social media: LinkedIn YouTube Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.